AH Equity Partners Bio II, L.L.C.
CIK: 0001725722
Associated companies
Transaction History
| NAUT | ▼ Sell | Open Market | 4,615,974 | $10.8M | 6/2/2026 | View on chart |
| NAUT | ▼ Sell | Open Market | 384,026 | $902K | 6/2/2026 | View on chart |
| NAUT | ▼ Sell | Open Market | 4,615,974 | $10.8M | 6/2/2026 | View on chart |
| NAUT | ▼ Sell | Open Market | 384,026 | $902K | 6/2/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Roth Capital initiates coverage on NAUT with $3.50 target
Roth Capital began tracking Nautilus Biotechnology with a Buy rating and a price target of $3.50. This new analyst note adds to the current consensus, where the average target from two analysts is $4.00. The stock is currently trading within its 52-week range of $0.72 to $4.31.
Roth Capital initiates coverage on NAUT with $3.50 target. Roth Capital began tracking Nautilus Biotechnology with a Buy rating and a price target of $3.50. This new analyst note adds to the current consensus, where the average target from two analysts is $4.00. The stock is currently trading within its 52-week range of $0.72 to $4.31.